Preparation, characterisation and entrapment of a non-glycosidic threitol ceramide into liposomes for presentation to invariant natural killer T cells by Kaur, Randip et al.
Preparation, characterisation and entrapment of a non-
glycosidic threitol ceramide into liposomes for presentation to
invariant natural killer T cells
Randip Kaur1, Jili Chen2, Amina Dawoodji2, Vincenzo Cerundolo2, Yoel R. Garcia-Diaz3,4,
Justyna Wojno3,4, Liam R. Cox4, Gurdyal S Besra3, Behfar Moghaddam1, and Yvonne
Perrie1,*
1School of Life and Health Sciences, Aston University, Birmingham, B4 7ET, UK
2Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, OX3 9DS, UK
3School of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
4School of Chemistry, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
Abstract
Dendritic cells (DCs) are able to present glycolipids to invariant natural killer T (iNKT) cells in
vivo. Very few compounds have been found that stimulate iNKT cells and of these the best-
characterised is the glycolipid α-galactosylceramide (α-GalCer 1), which stimulates the
production of large quantities of IFNγ and IL-4. However, αGalCer leads to overstimulation of
iNKT cells. It has been demonstrated that the αGalCer analogue, threitol ceramide (ThrCer 2),
successfully activates iNKT cells and overcomes the problematic iNKT cell activation-induced
anergy. In this study, ThrCer 2 has been inserted into the bilayers of liposomes composed of a
neutral lipid, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or
dimethyldioctadecylammonium bromide (DDA), a cationic lipid. Incorporation efficiencies of
ThrCer within the liposomes was 96 % for DSPC liposomes and 80 % for DDA liposomes with
the vesicle size (large multilamellar vs small unilamellar vesicles) making no significant
difference. Langmuir-Blodgett studies suggest both DSPC and DDA stack within the monolayer
co-operatively with the ThrCer molecules with no condensing effect. In terms of cellular
responses IFNγ secretion was higher for cells treated with small DDA liposomes compared to the
other liposome formulations, suggesting that ThrCer encapsulation in this liposome formulation
resulted in a higher uptake by DCs.
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1. Introduction
Invariant natural killer T (iNKT) cells are unique lymphocytes defined by their co-
expression of surface markers associated with NK cells along with a T-cell antigen
receptor.1 They recognise amphipathic ligands such as glycolipids or phospholipids
presented in the context of the non-polymorphic, MHC class I-like molecule CD1d.2 To
date, relatively few compounds have been found that stimulate iNKT cells. Of these, α-
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galactosylceramide 1 (α-GalCer 1) (Figure 1) is one of the most potent agonists and has the
ability to induce CD1d-restricted NKT cells specifically to produce high levels of both IL-4
(Th2) and IFNγ (Th1) in vitro and in vivo.3-5 iNKT cells in different situations display both
tolerogenic and immunostimulatory functions in vivo following αGalCer administration.
Unfortunately for therapeutic applications, αGalCer 1 leads to overstimulation of iNKT
cells; more specifically, it has been shown that a single injection of mice with 1-2 μg of
αGalCer induces long-term (> 30 days) anergy of iNKT cells.6,7 During this hyporesponsive
state, further activation of iNKT cells with αGalCer is unsuccessful. The production of both
Th1 and Th2 cytokines and the “unresponsive state” of iNKT cells after activation with
αGalCer renders this glycolipid of limited therapeutic use as a direct activator of iNKT cells
and has encouraged the development of αGalCer analogues that circumvent some of these
problems. To this end, we recently demonstrated that the αGalCer analogue, threitol
ceramide (ThrCer 2) (Figure 1), successfully activates iNKT cells and overcomes the
problematic iNKT cell activation-induced anergy associated with αGalCer 1.7 ThrCer 2 is a
promising agonist for iNKT cells and may have therapeutic application. It has been
previously demonstrated that this glycolipid, whilst preventing αGalCer-dependent iNKT
cell over-stimulation, ensures effective dendritic cell (DC) maturation, minimises iNKT cell-
dependent DC lysis, and promotes optimal expansion of antigen-specific T cell responses.7
Thus by minimising iNKT cell over-stimulation and iNKT cell-dependent DC lysis, ThrCer
rectifies some of the deficiencies of αGalCer.
ThrCer 2 is lipid-based with a molecular weight of 800 g/mol; it displays poor water
solubility. In an effort to improve this important physical characteristic and hence the ability
to deliver this immunostimulatory agent, we postulated that its incorporation into liposomes
would be useful. Liposomes are phospholipid vesicles consisting of one or several
concentric lipid bilayers, enclosing many aqueous compartments.8 Liposomes based on
dimethyldioctadecylammonium bromide (DDA) have previously been evaluated as carriers
for drugs9, as antimicrobial agents10 and as adjuvants11 for a range of vaccines for both
parenteral and mucosal delivery. In recent years, they have been used as part of more
complex adjuvant systems for experimental subunit vaccines.12,13 DDA was discovered as
an adjuvant by Gall in the mid 1960s14 and has been tested in combination with a number of
different viral and bacterial antigens in different animal species.15 It is a synthetic
amphiphilic lipid compound comprising a hydrophilic positively charged
dimethylammonium head-group attached to two hydrophobic 18-carbon alkyl chains. In an
aqueous environment, DDA assembles into closed vesicular bilayers similar to liposomes
made from natural phospholipids. The adjuvant activity of DDA has been thoroughly
reviewed by Hilgers and Snippe (1992), who assessed DDA to be a moderate or strong Th2
inducer and a strong Th1 inducer, and the mechanism of action behind the adjuvant effect of
DDA has been attributed to its positive surface charge and its ability to associate antigens.16
Recent studies provide support for this notion by showing that if DDA is replaced with a
neutral lipid such as 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), the neutralisation
of the surface charge of the liposomes diminishes their immunogenicity.17 Whilst the effect
of cationic liposomes on dendritic cells (DCs) is not well characterised in the literature, it is,
however, well known that cationic amphiphiles can be used as liposome carriers for nucleic
acids and thus enhance the transfection efficiency of cells in general.18
In this study, ThrCer 2 has been incorporated into the bilayers of liposomes composed of the
cationic lipid DDA or the zwitterionic lipid DSPC. These systems were prepared both as
multilamellar vesicles (MLV) and small unilamellar vesicles (SUV). The physiochemical
characteristics (vesicle size and entrapment efficiency) and biological activity of the
resulting liposomes incorporating ThrCer have been determined and these formulations were
then tested in terms of uptake and delivery of ThrCer to DCs and the ability of the DCs to
present ThrCer on CD1d molecules to iNKT cells leading to IFNγ release.
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2. Materials and Methods
2.1 Materials
Dimethyl dioctadecylammonium bromide (DDA) and 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC) were obtained from Avanti Polar Lipids (Alabaster, AL). The
purity of the compounds was > 99% by HPLC. Sephadex® G-75 was purchased from
Sigma-Aldrich Co. Ltd. (Dorset, UK). Fetal calf serum (FCS) was obtained from Biosera,
UK, IODO-GEN® pre-coated iodination tubes from Pierce Biotechnology (Rockford, IL),
and Ultima Gold scintillation fluid was purchased from Perkin Elmer (Waltham, MA).
Methanol (extra pure), chloroform (extra pure), ethanol (extra pure) and 1 M hydrochloric
acid, used to adjust pH in the Tris-buffer, were purchased from Fisher, UK. Tris (ultra pure)
was obtained from ICN Biomedicals (Aurora, OH). Threitol ceramide (ThrCer, 2) and
radiolabelled ThrCer, 14C-ThrCer, 14C-2, was prepared as previously described.19
2.2 Methods
2.2.1 Preparation of liposomes—DDA and DSPC liposomes with and without the
addition of ThrCer were prepared by the lipid hydration method.8 The lipids and ThrCer
used in these experiments were dissolved in chloroform:methanol (2:1 v/v). DDA or DSPC
(30 μL of a 10 mg ml−1 solution) and ThrCer (60 μL of a 1 mg ml−1 solution) were placed in
a 50 ml round-bottom Quick-fit flask and the organic solvent was removed by rotary
evaporation at about 37 °C to yield a thin lipid film on the walls of the flask, which was
flushed with oxygen-free nitrogen (N2) in order to ensure complete removal of solvent. The
vesicles were formed by hydrating the lipid film in Tris-buffer at pH 7.4 (600 μL of a 10
mM solution). The lipid film was hydrated for 20 min at a temperature of 10 °C above the
main phase transition of either DDA (Tm ~47 °C) or DSPC (Tm ~55 °C) respectively to
ensure complete hydration.
For the generation of small unilamellar vesicles (SUV), the multilamellar vesicles (MLV)
produced were disrupted by sonication using a probe sonicator (Soniprep 150), to fracture
the large liposomes into smaller structures. The DSPC liposome batches were sonicated for
1 min, whereas the DDA liposomes were sonicated for 30 s to produce SUV.
2.2.2 Measuring entrapment of ThrCer in DSPC and DDA liposomes—The
degree of ThrCer incorporated in the liposomes was determined by tracking 14C-labelled
ThrCer. 14C-Radiolabelled ThrCer (10 μl of a 1 mg ml−1 solution) was incorporated into
liposomes prepared as described above. The DSPC or DDA 14C-ThrCer liposomes (400 μl)
were placed into dialysis tubing (molecular weight cut off (MWCO) of 12,000 or greater),
and transferred into Tris buffer (500 ml of a 10 mM solution, pH 7.4). At various time-
points, ThrCer incorporation and release from the liposome formulations was determined by
removing 1 ml sample from the receiver solution, which was subsequently replaced with 1
ml Tris buffer, in order to maintain sink conditions. Incorporation of ThrCer was determined
on the basis of 14C-labelled ThrCer remaining in the liposome suspension after dialysis.
2.2.3 ThrCer retention in simulated in vivo conditions—ThrCer release from
liposomes stored in simulated in vivo conditions was determined using liposomes
entrapping 14C-radiolabelled ThrCer prepared as described in Section 2.2.1. Aliquots of
each formulation were diluted (1:5) using 50% FCS in Tris buffer and incubated in a
shaking water bath at 37 °C for 28 days. At time intervals, samples were centrifuged
(125000×g, 4 °C, 1 h), resuspended in Tris buffer and centrifuged again to ensure removal
of all non-incorporated ThrCer. The 14C-ThrCer recovery in the pooled supernatant after
two washes (non-incorporated ThrCer) and the pellet (incorporated ThrCer) was measured.
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The percentage of ThrCer entrapped was calculated as a percentage of the total radioactivity
recovered from both supernatant and pellet.
2.2.4 Determination of liposome size—The vesicle size of DDA and DSPC liposomes
with and without the inclusion of ThrCer was determined using the photon correlation
spectroscopy (PCS) technique. The measurements were performed at 25 °C using a ZetaPlus
(Brookhaven Instrument Corporation, USA). Polystyrene size standards 220 ± 6 nm (Duke
scientific corp, Duke, NC) was used as a control. For viscosity and refractive index, the
values of pure water were used (0.89 cp and 1.0, respectively). The samples were diluted
with 10 mM Tris-buffer at pH 7.4 to achieve the optimal vesicle concentration.
2.2.5 Langmuir-Blodgett isotherms—An automated controlled film balance apparatus
(KSV Langmuir Mini-trough, KSV Instruments Ltd, Helsinki, Finland) equipped with a
platinum Wilhemy plate and placed on a vibration-free table was used to collect the surface
pressure-area isotherms as previously reported (Christensen et al 2008). The size of the
trough was 24,225.0 mm2 enclosing a total volume of approximately 220 ml; the subphase
was composed of filtered double-distilled water. The compounds (at fixed total
concentration of 1 mg ml−1) were dissolved in chloroform and 20 μl of each solution was
spread onto the air/water interface with a Hamilton microsyringe, precise to ± 0.2 μl. After
spreading, the monolayers were left for 10 min to allow the chloroform to evaporate.
Thereafter, the molecules underwent constant compression (10 mm s−1) until the required
surface pressure of less than 0.2 mN/m was attained. The spread monolayer was then
compressed or expanded symmetrically with the two barriers until the desired surface
pressure was reached with accuracy within 0.1 mN/m. The temperature of the subphase was
kept constant at 20 ± 1 °C by means of an external water bath circulation system. The
temperature of 20 °C is close to the chain-melting transition temperature of DSPC and is
thus suitable to clearly see the domain formation in a monolayer. At the same time,
evaporation from the subphase at this temperature is limited and does not hinder the
experiment. Each experiment was only compressed once and was performed three times
with monolayers prepared from different solutions. KSV software (KSV Instruments Ltd,
Helsinki, Finland) was used for data analysis.
2.2.6 Liposome presentation to invariant natural killer T cells—Peripheral blood
mononuclear cells (PBMCs) were isolated from healthy donors’ buffy coats by density
gradient centrifugation over Lymphoprep (Nycomed). Monocytes were positively selected
using anti-CD14 mAb-coated magnetic beads (MACS; Miltenyi Biotec) and were then
cultured in 6-well plates in either X-Vivo 15 + 2% Human AB serum with 800 U ml−1
granulocyte monocyte colony stimulating factor (GM-CSF) and 500 U ml−1 IL-4 for 4 days
to produce immature DCs. On day 4, liposomes (1 μg ml−1 or 100 ng ml−1), lab grade
ThrCer (1 μg ml−1) and α-GalCer (100 ng ml−1) were added to the immature DCs, followed
by the addition of maturation cocktail (IL-1β, IL-6, TNF-α and PGE2) after 3 h. DCs were
harvested and assayed with iNKT cells overnight, the supernatants were taken and an IFNγ
ELISA performed. DCs were also analysed by FACS after addition of liposomes for
expression of CD83, CD80 and CD86 to see whether there is any contamination of
liposomes.
2.2.7 IFNγ ELISA—ELISA plates were coated with 1D1K antibody (Mabtech) and left
overnight at 4 °C. Plates were washed with 0.05% tween 20 in PBS (v/v). To eliminate any
non-specific antigen binding, the plates were coated (i.e. blocked) with 200 μL of 10% FCS
in PBS (v/v) and incubated for 2 h at 37 °C. 100 μL of reaction supernatant was transferred
to the ELISA plate and the standard was added starting at 50 ng ml−1. The plate was then
incubated at 4 °C overnight. The following day, the plates were washed with 0.05% tween
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20 in PBS and the biotinylated anti-cytokine detecting mAb was added at 50 μL/well and
incubated at room temperature for 2 h. After incubation, the plates were washed eight times
with 0.05% tween 20 in PBS. 100 μL of working dilution of avidin-peroxidase was added
per well after which the plates were incubated at room temperature for 2 h. Plates were once
again washed eight times with 0.05% tween 20 in PBS. 100 μl of tetramethylbenzidine
(TMB) agent was added per well. Reaction was stopped with 50 μl solution of 0.5 M H2SO4
and the optical density of each well was measured immediately using a microplate reader
(Bio-Rad, model 680) set to 450 nm.
2.2.8 Statistical analysis—Data was analysed using analysis of variance (ANOVA)
followed by Tukey test was performed to compare the mean values of different groups.
Differences were considered significant when p< 0.05. Each value was obtained from
triplicate samples from each case and expressed as mean ±SD.
3. Results and discussion
3.1 Characterisation of ThrCer liposomes
As discussed, cationic liposomes based on DDA have been evaluated and have shown
potential as an adjuvant system for vaccines against a wide range of diseases.15 In this study,
two liposomal delivery systems composed of DDA and DSPC (a neutral alternative) were
tested for their ability to enhance ThrCer delivery to DCs. Table 1 provides size,
polydispersity and ThrCer loading of the liposomal systems with and without the inclusion
of ThrCer when formulated in both multilamellar vesicles (MLV) and small unilamellar
vesicles (SUV).
The addition of ThrCer to DSPC liposomes was found to significantly (p <0.05) reduce the
size of both MLV and SUV liposomes (Table 1). However in contrast, for the DDA-based
liposomes a significant increase (p <0.05) in size was found for MLV liposomes but no
significant change in size was noted for SUV liposomes (Table 1). The changes in size seen
in both sets of formulations suggest that ThrCer promotes a re-organisation of surfactants
within the bilayers, and in the case of the DSPC liposomes promoting smaller sized vesicles.
A similar effect with small-molecule drugs was found by Lopes et al20, where sodium
diclofenac, an amphiphilic molecule, interacted with the bilayers of liposomes composed of
soya phosphatidylcholine, causing a decrease in liposome size. Several other studies have
also suggested molecular association between amphiphilic drugs and phospholipids
including anti-inflammatory compounds, results in a decrease in the size of liposome
structures.21-23 Interestingly, the effect of ThrCer on DDA liposomes was in contrast, with
its addition promoting slightly larger vesicle sizes suggesting possibly the charge of the lipid
headgroup was playing an influencing role.
Incorporation of ThrCer was also influenced by the charge of the lipids employed with
cationic liposomes prepared from DDA having a reduced loading compared to their
zwitterionic counterpart; both MLV and SUV liposomes prepared using DSPC incorporated
more ThrCer than their cationic DDA counterparts (Table 1). This suggests that the
zwitterionic lipid DSPC is better able to accommodate the ThrCer within the bilayer
structure compared to DDA.
3.2 Determination of vesicle stability over time
Stability was investigated in terms changes of vesicle size over time, the 8 formulations
were prepared and stored at room temperature (25 °C) for 28 days (Figure 2a and b). Whilst
after the initial preparation, the DSPC MLV were 1346.6 ± 267.0 nm, the size of these
vesicles increased rapidly on storage to 1944.2 ± 102.2 nm after 14 days and after 28 days
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storage visible aggregation became apparent (Figure 2a). In contrast, addition of ThrCer to
these DSPC liposomes promoted enhanced stability with liposomes showing no significant
change (p <0.05) in particle size over the 28 day period with sizes remaining around 296.1±
39.2 nm, indicating that the presence of ThrCer in the DSPC liposome bilayers leads to
improved liposome stability potentially through promoting the reduced vesicle sizes which
were less likely to sediment and aggregate (Figure 2a).
The MLV liposomes produced with DDA alone again showed instabilities in terms of
particle size when stored at room temperature with a twofold increase in size being noted
over the 28 day study (Figure 2a), however unlike the DSPC liposomes the addition of
ThrCer did not improve the stability of DDA liposomes with vesicle size increasing by 59 %
over the 28 days. These results could again suggest that the smaller vesicle size of the
DSPC-ThrCer liposomes (~175 nm; Table 1) compared to the larger MLV DDA liposomes
(~409 nm) was supporting their improved stability. However this is not supported by
stability studies of SUV formulations (Figure 2b). Of the four SUV formulations, again only
the DSPC:ThrCer liposomes showed no significant change (p >0.05) in size over the 28 day
period with sizes remaining around 177 nm, whilst DSPC only SUV increased by 57 % from
their initial size (Figure 2b). The DDA SUV with and without ThrCer also showed size
instability over time with particle sizes increasing from around 100 nm to 300 nm by day 14
with no further significant changes in size thereafter (Figure 2b). Therefore whilst both
liposome size and surface charge in general are known to have an influencing effect on the
rate of sedimentation and potential aggregation, the change in lipid packaging with the
addition of ThrCer to liposomes formulated as both MLV and SUV improved DSPC
liposome stability but not those based on DDA.
3.3 ThrCer is retained in liposomes under simulated in vivo conditions
For therapeutic application, it is important that drugs are retained within liposomes for an
appropriate time, and release kinetics may vary depending on the drug delivered, the site of
action and the therapeutic application. Among the various factors that dictate the liposomal
release of a drug, the bilayer composition is a key factor.24 ThrCer retention was measured
in simulated in vivo conditions i.e. in 50% FCS in Tris buffer and compared to control with
formulations only in Tris buffer. The percentage of ThrCer incorporation was calculated as a
percentage of the total radioactivity recovered from both supernatant and pellet in both
conditions. In all four of the formulations tested high levels of ThrCer retention was
measured in the presence of 50 % FCS (Figure 3). In the case of the MLV formulations
(Figure 3a), the DSPC:ThrCer and DDA:ThrCer MLV retained over 88 % and 80 % of the
initial ThrCer loading over the period of the study (Figure 3a) with 7 % being lost over the
initial 24 hour period.
For the SUV-based formulations (Figure 3B), both the DSPC and DDA based vesicles gave
significantly higher (p <0.05) ThrCer release in serum over time compared to the MLV, with
DSPC vesicles showing ThrCer retention of 63 % and DDA vesicles 69 %. This increased
instability of the SUV compared to the MLV maybe an outcome of the larger total surface
area of these SUV suspensions which results in higher interactions of the lipids with the
serum moieties. In general releases in serum were higher than those measured for Tris buffer
(Figure 3).
3.4 Langmuir-Blodgett isotherms
To investigate the packaging of ThrCer with the DDA or DSPC surface pressure/area
isotherms of monolayers of the lipids on their own or in combination were investigated.
Such monolayer studies can be used to thermodynamically analyse interactions between
components in mixed monolayers, allowing interactions between lipid components and their
Kaur et al. Page 6
J Pharm Sci. Author manuscript; available in PMC 2013 November 06.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
molecular arrangement at the air/water interface.25 It is clear that the structural differences
of lipids influence the interactions among them and these interactions dominate the
organisation of membranes.26 Many studies have been conducted on the behaviour of
different lipids in mixed monolayers27,28 and these can be used to interpret interaction is in
liposome bilayers.29,30 Surface properties of mixed monolayers are generally studied on the
basis of surface pressure (π)/mean molecular area (A) measurements in which bidimensional
phases can be detected, each separated by a phase transition. The 2D phases in increasing
pressure order are (1) bidimensional gas, (2) expanded liquid, (3) liquid, (4) condensed
liquid, and (5) solid. Once the solid phase has been reached and the pressure is further
increased, collapse occurs, i.e., the monolayer breaks and aggregates or multilayers are
formed. Importantly, the shape and location of the isotherms are indicative of the
interactions both between molecules in the monolayer and of the subphase. To investigate
the geometrical interactions between DSPC or DDA with ThrCer at the air/water interface
surface pressure studies of the various surfactants and mixtures were investigated (Figure 4a
and b, with calculations presented in Table 2).
The isotherm of pure DSPC (one component system) shows the molecular area as 48.2 ± 2.7
A2 per molecule and the condensed phase collapsing at 58.5 ± 0.6 mN m−1 (Figure 4a; Table
2), which are in agreement with results collated by Cardenas et al31. For DDA, monolayer
collapse occurred at 44.8 ± 1.9 mN m−1, similar to literature reports of DDA on pure water,
which was found to be 45 mN m−1 32,33 (Figure 4b; Table 2). Of the three pure molecules,
ThrCer has a smallest area/molecule of 27.2 ± 1.3 A2 per molecule and a collapse pressure
similar to DSPC of 60.3 ± 2.4 mN m−1, which would be expected from this type of
surfactant structure (a small headgroup and saturated tail groups; Figure 1).
In both cases, the isotherms of the lipid mixtures were found to lie between the ranges of
those of the pure components (Figure 4a and b) and for both the DSPC:ThrCer and
DDA:ThrCer mixtures the measured extrapolated area per molecule was significantly higher
than the predicted A2 per molecule (5 % deviation for the DSPC:ThrCer mix and 14 % for
the DDA:ThrCer mix; Table 2). It has been suggested34 that positive deviation (which is
when the experimental area is more than the ideal area) occurs with saturated lipids which
stack co-operatively and that there is no condensing effect as is noted when lipids such as
DSPC are mixed with cholesterol.30
In terms of monolayer collapse pressure, the addition of ThrCer to DSPC made no
significant difference to the collapse pressure of the monolayer. In contrast, ThrCer was
shown to significantly increase the surface pressure at which the monolayer collapsed
compared to DDA alone (increasing the collapse pressure by 8.7 mN/m; Table 2). Recent
surface pressure studies of DDA in combination with trehalose 6,6′dibehenate (TDB)29 have
shown that the addition of TDB to DDA monolayers increased the collapse pressure
compared to DDA alone indicating that the attractive forces between the trehalose
headgroup of TDB and water are greater than those between the quaternary ammonium head
group of DDA and water. From the data in Figure 4b, it would suggest that ThrCer is having
a similar effect and improving the interaction of the monolayer mixture with water.
However this did not translate into improved stability as seen in Figure 2, whilst the addition
of ThrCer to DSPC liposomes was seen to improve their stability, this was not the case with
DDA liposomes (Figure 2) and it may be that higher concentrations of ThrCer than those
employed in the liposomes would be required to stabilise the cationic formulations.
In general, these collapse pressures at high surface pressure and small molecular area can be
attributed to the lipids (DDA, DSPC and ThrCer) used for the study which are saturated
lipids. Previous studies noted that when a lipid is unsaturated with one or more double
bonds, which in most naturally occurring lipids are in the cis configuration, this makes the
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chain bend and accordingly, the more double bonds the chain has in the cis configuration,
and the more curved the chain.34 This results in a decreased packaging efficiency and an
increased area per molecule. In contrast, saturated lipids are known to form straight chains
resembling rods. The saturated lipids therefore occupy a smaller molecular area than
unsaturated lipids and their collapse pressure is higher.25
3.5 Uptake of ThrCer by DCs
The uptake of the immunostimulatory agent, ThrCer by DCs, and presentation on CD1d
molecules to iNKT cells were determined by measuring IFNγ release (Figure 5). Previous
studies have shown that ThrCer efficiently activates iNKT cells, resulting in DC maturation
and activated iNKT cells rapidly produce IFNγ.7 To examine whether both the cationic and
neutral ThrCer-containing liposomes were able to enhance this action, we measured
secretion of IFNγ by iNKT cells stimulated with different concentrations (1 μg ml−1 and 100
ng ml−1) of liposomes, which were loaded on to DCs. The results (Figure 5) show that both
types of ThrCer-containing liposomes could sufficiently activate iNKT cells. When
comparing concentration of ThrCer, 1 μg ml−1 and 100 ng ml−1, a higher IFNγ secretion
was found at higher concentrations for all formulations. In particular the DDA SUV based
liposome formulation was found to produce a higher IFNγ secretion at both concentrations 1
μg ml−1 and 100 ng ml−1compared to the neutral DSPC based liposomes. In all cases the
negative control liposomes (not containing ThrCer) induced minimal levels of IFNγ
secretion.
Only a few compounds stimulate iNKT cells, the best characterised is the glycolipid α-
GalCer, which stimulates the production of large quantities of IFNγ and IL-4 by these cells.
However, αGalCer 1 leads to overstimulation of iNKT cells. ThrCer 2 successfully activates
iNKT cells and overcomes the problematic iNKT cell activation-induced anergy associated
with αGalCer 119. From this data it has been demonstrated that the IFNγ secretion was
higher for the DDA SUV based formulation, suggesting that ThrCer encapsulation in this
liposome formulation resulted in a higher uptake by dendritic cells.
Previous studies have shown that DDA is an effective type of adjuvant promoting a cell-
mediated immune response against intracellular pathogen M. tuberculosis.12 A number of
studies have looked at DDA and other immunomodulating agents.35,36 Administration of
Arquad 2HT, which comprises DDA, in humans was promising and did not induce apparent
side effects.35 An experimental vaccine based on culture filtrate proteins from M.
tuberculosis and DDA generated a protective immune response against TB in mice.36
Moreover, DDA has been used as an adjuvant for a DNA vaccine against pseudorabies virus
leading to enhanced T-cell responses and antiviral immunity.37
4. Conclusion
ThrCer 2, a new class of immunostimulatory agent, has been entrapped in DSPC and DDA
liposomes, MLV and SUV, respectively. The entrapment efficiency of ThrCer within the
lipid bilayers was high for both zwitterionic (DSPC) and cationic (DDA) liposomes. The
release of ThrCer from liposomes was measured in Tris and 50% FCS (to simulate in vivo
conditions) and it was found that both the MLV based formulations had a higher ThrCer
retention compared to the SUV counterparts. In terms of ThrCer packaging it was found that
the addition of ThrCer improved the stability of the DSPC liposomes, however this was not
the case for the DDA-based liposomes and it may be that higher concentration of ThrCer
than those employed in the liposomes would be required to stabilise the cationic
formulations. For the in vitro work, it was demonstrated that the IFNγ secretion was higher
for DDA SUV liposome formulation (p <0.05), suggesting that whilst these systems had
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reduced stability compared to their DSPC counterparts, ThrCer encapsulation in this
liposome formulation resulted in a higher uptake by dendritic cells.
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Figure 1.
CD1d agonists αGalCer 1 and ThrCer 2.
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Figure 2.
Vesicle size (nm) of MLV (a) and SUV (b) of DSPC and DDA liposomes with and without
the inclusion of ThrCer represented by storage at 25 °C. Size were measured in Tris buffer
(1 mM) using a Brookhaven ZetaPlus instrument. Results represent mean ± SD of triplicate
experiments.
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Figure 3.
Entrapped ThrCer release profile of DSPC and DDA MLV (a) and SUV (b) from liposomes
when stored in Tris and under simulated in vivo conditions (50% FCS, 37 °C).
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Figure 4.
The surface pressure-area isotherms of mixed and pure monolayers at the air/water interface.
The mixed and pure monolayers were of (a) DSPC, (b) DDA and ThrCer. The air/water
interface was at 20 °C. Results denote mean ± SD, from 3 independent batches.
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Figure 5.
IFNγ release from iNKT cells co-cultured with DCs pulsed with liposomes
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Table 1
Characterisation of MLV or SUV liposomes prepared from DSPC or DDA with and without the inclusion of
ThrCer. Size (nm) and polydispersity (PI) were measured by photon correlation spectroscopy. Results
represent mean ± SD for 3 independent batches.
Formulation MLV SUV
Size (nm) Polydispersity
Index (PI)
ThrCer loading
(% of amount
used)
Size (nm) Polydispersity
Index (PI)
ThrCer loading
(% of amount
used)
DSPC 1346.6 ± 267.0 0.378 ± 0.00 - 228.4 ± 3.20 0.302 ± 0.03 -
DSPC-ThrCer 174.5 ± 3.10 0.324 ± 0.05 96 ± 2.5 % 121.1 ± 2.30 0.302 ± 0.00 94 ± 2.8%
DDA 408.7 ± 14.90 0.345 ± 0.03 - 103.1 ± 1.40 0.296 ± 0.07 -
DDA-ThrCer 572.8 ± 18.30 0.327 ± 0.03 80 ± 1.2% 121.2 ± 4.70 0.357 ± 0.00 74 ± 4.2%
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Table 2
The experimental extrapolated area and area compressibility of mixed and pure monolayers at the air/water
interface (at 20 °C) by DSPC, DDA and ThrCer in dH2O. Results denote mean ± SD, from 3 independent
batches.
Formulation Extrapolated
area at zero
pressure (A2/Molecule)
Ideal
Extrapolated area
at zero pressure
(A2/Molecule)
Deviation
from
ideality (%)
Collapse pressure
(mN m−1)
DSPC 48.1 ± 2.7 - - 58.5 ± 0.6
DDA 61.5 ± 2.7 - - 44.8 ± 1.9
ThrCer 27.2 ± 1.3 - - 60.28 ± 2.4
DSPC:ThrCer (1:1) 42.6 ± 2.6 37.65 + 4.95 57.1 ± 1.1
DDA:ThrCer (1:1) 50.4 ± 2.6 44.35 + 13.64 63.5 ± 1.5
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